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lncRNA profiling in early-stage chronic lymphocytic leukemia
identifies transcriptional fingerprints with relevance in clinical
outcome
D Ronchetti1,11, M Manzoni1,11, L Agnelli1, C Vinci1, S Fabris2, G Cutrona3, S Matis3, M Colombo3, S Galletti1, E Taiana2, AG Recchia4,5,
S Bossio4,5, M Gentile4, C Musolino6, F Di Raimondo7, A Grilli8, S Bicciato8, A Cortelezzi1,2, P Tassone9, F Morabito4,5, M Ferrarini10 and
A Neri1,2
Long non-coding RNAs (lncRNAs) represent a novel class of functional RNA molecules with an important emerging role in cancer.
To elucidate their potential pathogenetic role in chronic lymphocytic leukemia (CLL), a biologically and clinically heterogeneous
neoplasia, we investigated lncRNAs expression in a prospective series of 217 early-stage Binet A CLL patients and 26 different
subpopulations of normal B-cells, through a custom annotation pipeline of microarray data. Our study identified a 24-lncRNA-
signature specifically deregulated in CLL compared with the normal B-cell counterpart. Importantly, this classifier was validated on
an independent data set of CLL samples. Belonging to the lncRNA signature characterizing distinct molecular CLL subgroups, we
identified lncRNAs recurrently associated with adverse prognostic markers, such as unmutated IGHV status, CD38 expression, 11q
and 17p deletions, and NOTCH1 mutations. In addition, correlation analyses predicted a putative lncRNAs interplay with genes and
miRNAs expression. Finally, we generated a 2-lncRNA independent risk model, based on lnc-IRF2-3 and lnc-KIAA1755-4 expression,
able to distinguish three different prognostic groups in our series of early-stage patients. Overall, our study provides an important
resource for future studies on the functions of lncRNAs in CLL, and contributes to the discovery of novel molecular markers with
clinical relevance associated with the disease.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous
disease.1,2 Over the past two decades, several studies have shown
a relationship between such heterogeneity and the presence of
cellular and molecular markers, such as IGHV mutational status,3
cytogenetic abnormalities and gene mutations.4–13 In recent years,
great attention has been devoted to long non-coding RNA
(lncRNA) molecules, a large class of transcripts that represent over
half of the mammalian non-coding transcriptome. LncRNAs are
involved in many biological processes, such as transcriptional
gene regulation, maintenance of genomic integrity, genomic
imprinting, cell differentiation or development.14,15 Their dereg-
ulation promotes tumor formation, progression and metastasis in
many types of cancer,16 including hematologic malignancies.17,18
In addition, recent evidence has suggested and/or demonstrated
an interplay of the various non-coding species, especially lncRNAs
and miRNAs, in cancer development.19 The number of known
human lncRNA transcripts is still evolving. To date, approximately
110 000 human lncRNAs are annotated in LNCipedia repository,
with many loci generating multiple transcripts.20
The knowledge of the role of lncRNAs in CLL is virtually absent.
Garding et al.21 provided insights into the epigenetic mechanisms
regulating the expression of the DLEU1 and DLEU2 genes,
mapped to the critical region at chromosomal band 13q14.3
which is deleted in over 50% of patients with CLL.9,22 DLEU2 hosts
the miR-15a/16-1 cluster, known for its crucial role in CLL
pathogenesis.23 The only additional evidence of the involvement
of lncRNAs in CLL suggest a role for NEAT1 and lincRNA-p21 as
novel elements of the p53-dependent DNA damage response
machinery.24
Herein, we investigated the lncRNA expression profiles in a
large prospective series of Binet A CLL patients and in distinct
populations of normal B-cells, isolated from tonsils and peripheral
blood B-lymphocytes. Additionally, we searched for a putative
significant correlation between lncRNAs and miRNAs at expression
levels. Finally, lncRNA expression patterns were correlated with
prognosis and prognostic markers to outline their possible role in
CLL outcome.
PATIENTS AND METHODS
Patients
The study included 217 newly diagnosed CLL patients prospectively
enrolled from several Italian institutions in an observational multicenter
study (clinicaltrial.gov #NCT00917540), as previously described.25
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Peripheral blood mononuclear cells from CLL patients and healthy
donors, and B-cell populations from tonsils (i.e. naïve B-cells (N), marginal
zone (MZ)-like, germinal center (GC), switched memory (M) B-cells),
tonsillar and bone marrow plasma cells were obtained as previously
described.25 Highly enriched CD19+ B-cells were characterized for IGHV
mutational status, CD38 and ZAP70 expressions, NOTCH1 mutations, and
cytogenetic alterations, that is, deletion of chromosome 13q (del13q), 11q
(del11q), 17p (del17p) and trisomy chromosome 12 (12+), as previously
described.12,26–29
Transcriptional analyses
The expression profiles of the 217 samples was generated using GeneChip
Gene 1.0 ST Array (Affymetrix Inc., Santa Clara, CA, USA) as previously
described,30 and data have been deposited in the NCBI Gene Expression
Omnibus database (GSE46261). To detect lncRNA expression, we applied a
custom pipeline able to re-annotate the probes included in the Gene 1.0 ST
expression array according to the LNCipedia-v3.1 annotation database.
MiRNA profiling of the 217 samples was generated using Agilent Human
miRNA microarray (G4470B; Agilent Technologies, Santa Clara, CA, USA).31
Principal component analysis was performed by singular value
decomposition of the considered data expression matrix using the prcomp
function in the stats package, and the results visualized using the plot3d
function in the rgl package for R software. Supervised analyses were
performed using the Significant Analysis of Microarrays (SAM) software
version 5.0032 using the web application provided in the shiny package for
R software (https://github.com/MikeJSeo/SAM). The differentially
expressed lncRNAs discriminating CLL and normal B-cell counterpart were
identified using Prediction Analysis of Microarrays as previously
described.33 Hierarchical agglomerative clustering of patients was per-
formed adopting Pearson's correlation and average as distance and
linkage methods, respectively. Functional characterization of lncRNAs was
performed using the GSEA software v.2.2.134 and the gene sets from
Hallmarks, Kegg and Reactome collections. Ranking of coding genes from
genes sets used the lncRNAs expression as a continuous phenotype and
the Pearson’s correlation as metric. Gene sets were considered significant if
the false discovery rate was ⩽ 0.25 under 1000 permutations.
Statistical analysis
The Cox proportional-hazards model in the Globaltest package for R was
used to test the association between lncRNA expression levels, assumed as
continuous variables, and progression-free survival (PFS) in terms of time-
to-first-treatment as clinical outcome. Globaltest was run with 100 000
permutations on lncRNAs that varied mostly over the data set, namely
those whose standard deviation of the expression exceeded the median
plus one median absolute deviation of all the standard deviations. The list
of significantly associated lncRNA to the PFS was reduced to derive a
prognostic lncRNA signature: briefly, k-means clustering was applied to
each lncRNA to define high- and low-expressing samples and then test the
clinical outcome of the two groups. The survival distributions identified by
this approach were tested using Kaplan–Meier estimator and log-rank test,
and P-values were calculated according to the standard normal asymptotic
distribution (survdiff function of the survival R package). The Benjamini–
Hochberg method was applied for multiple testing corrections. Indepen-
dence between lncRNA models and common CLL prognostic factors (IGHV
mutational status, CD38, ZAP70, NOTCH mutation and unfavorable
cytogenetic aberrations, namely del11q, del17p and 12+) was assessed
using the multivariate Cox proportional-hazards regression procedure by
the coxph function in the survival R package. Kendall Tau correlations and
Wilcoxon rank-sum tests were applied using standard functions in R base
package.
miRNA targets custom predictions were obtained for lncRNA sequences
using RNA-22 version 2.0 prediction algorithm,35 which allows customizing
input sequences and parameters (https://cm.jefferson.edu/rna22/Interac
tive/). The RNA-22 perl script was run on the combination of the 286 miRNA
and 395 lncRNA FASTA sequences obtained from the correlation analysis
(Po0.05 after multiple testing adjustment). The default sensitivity/
specificity ratio of 1.032 was chosen, and provided a minimum seed size
of seven bases with only one mismatch exception, a minimum number of
12 paired-up bases in heteroduplex with − 12 kcal/mol maximum folding
energy, and no more than one G-U wobble in the seed region.
RESULTS
LncRNA expression profiles in CLL and in distinct subgroups of
normal B-cells
The lncRNAs expression profiles of leukemic cells from a cohort of
217 patients with early stage, Binet A CLL were investigated
(Supplementary Table S1)25 and compared with those of different
types of normal B-cells. These samples included six peripheral
B-cell (pBC), four GC, three N, two MZ, three M, four tonsillar
plasma cells and four bone marrow plasma cells.
To detect lncRNA expression, we applied a custom pipeline able
to re-annotate the probes included in the Gene 1.0 ST expression
array according to the LNCipedia annotation database. Such a
strategy allowed us to investigate the expression levels of 1852
well-annotated and specific human lncRNAs, as previously
reported.36
Firstly, we searched for the B-cell subset sharing lncRNA
expression similarities with CLL cells. Clustering analysis of the
26 normal B-cell subtypes was run on the 141 lncRNAs varying at
least 1.5-fold in expression levels from the mean across the data
set. Distinct lncRNAs profiles were associated with tonsillar plasma
cells, bone marrow plasma cells, pBCs and GC cells, whereas M, MZ
and N B-cells presented undistinguishable expression profiles and
were considered as part of a single cluster (Figure 1a). Among
these five B-cells clusters, multiclass SAM analysis identified 226
differentially expressed lncRNAs (Supplementary Figure S1) that
were subsequently used to compare normal B-cell subsets with
CLL samples. The principal component analysis analysis revealed
that CLL were more similar to tonsillar MZ, M and N B-cells than to
GC cells, pBCs, tonsillar plasma cells or bone marrow plasma cells
(Figure 1b). This finding is similar to that reported by our previous
study in the context of miRNA and small nucleolar RNA (snoRNAs)
expression in the same CLL data set.25,31 Given the similarities of
the lncRNA profile among CLL cells, tonsillar MZ, M and N B-cells
as a whole were chosen as the 'comparator' B-cells to unravel
lncRNA expression alterations in CLL. The classifier was first trained
on an unbiased randomly selected cohort of 109 CLL cases
(training set), and then applied to a validation set including the
108 remaining samples (Supplementary Table S1). The minimum
error corresponded to 24 discriminant lncRNAs expression profiles
between CLLs and comparator B-cells, leading to a good
classification accuracy when applied to the validation patient set
(overall: 99.14%; specificity: 100%; sensitivity: 99.07%) (Figure 1c).
Specifically, the 14 lncRNAs that were downregulated in CLL
included lnc-TOMM7-1 (showing the lowest expression ratio
CLL/comparator) and 8 lncRNAs that are located in chromosomal
regions, such as 14q32, 2p and 22q, coding for the highly variable
portions of the immunoglobulin genes or for IGHV pseudogenes.
The lncRNAs classifier included 10 lncRNAs that were upregulated
in CLL samples, among which lnc-SNX29P2-3 and lnc-SEL1L3-6
(see below).
Importantly, the 24-lncRNA classifier signature was validated on
a publicly available independent cohort including 9 CLL and 10
normal samples, profiled on the same array.37 Specifically, we
verified the predictive power of the 24-lncRNA model using leave-
one-out and linear discriminant analysis as the cross-validation
procedure and prediction method, respectively, and demon-
strated its capability to discriminate robustly CLL from normal
B-cell samples (overall accuracy: 100%, Supplementary Figure S2).
LncRNA expression in different CLL prognostic subgroups
CLL patients can be stratified into different prognostic groups
based upon the presence/absence of cellular, molecular or
cytogenetic markers. Here, we aimed at identifying specific
lncRNAs signatures associated with each of these CLL subgroups
(specified in Supplementary Table S1). We compared lncRNA
expression of IGHV mutated (M-CLL, n= 131) vs unmutated
(UM-CLL, n= 85) patients. The analysis identified 30 differentially
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expressed lncRNAs (Supplementary Table S2). To reduce biases
possibly due to group heterogeneity (i.e., the distribution of
cytogenetic alterations within the two IGHV classes), we restricted
the analysis to a homogeneous CLL subgroup with del13q as
common and sole abnormality, including 31 UM and 73 M-CLLs.
This approach led to the identification of 12 differentially
expressed lncRNAs (Table 1), 10 of which were already detected
in the comparison of unselected M- and U-CLL (Supplementary
Table S2). In particular, we identified an upregulation of the lnc-
IRF2-3 mapping at 4q35 and lnc-AC004696.1-1, which is located
antisense, head to head, to ZNF667 gene at 19q13.
Overall, 12 and 20 lncRNAs distinguished CLL stratified based on
ZAP70 or CD38 expression levels, respectively (Supplementary
Tables S3 and S4). Among them, five lncRNAs (lnc-IRF2-3, lnc-
AC004696.1-1, lnc-TNFRSF13B-5, lnc-C1orf132-1 and lnc-BACH1-1)
were common to those identified in the above analysis
(Supplementary Figure S3), which is in line with the notion that
CD38 and ZAP70 represent in part surrogate markers of IGHV
mutational status.
To identify lncRNA expression patterns characterizing the major
cytogenetic aberrations, all the FISH 'negative' CLLs were
considered as normal counterpart (78 patients). In addition, when
del13q occurred with another cytogenetic abnormality, the latter
was considered predominant for group inclusion. The results of
each analysis are reported in Supplementary Tables S5–S8, while
the most significant lncRNAs (top 10 score) are reported in Table 1.
In detail, del13q patients showed an upregulation of lnc-SEL1L3-1,
lnc-AMZ1-6, lnc-DTNB-2 and lnc-SNX29P2-3 (Supplementary Table
S5), which were also downregulated in the comparator normal
B-cells with respect to CLL samples (Figure 1c), and the
downregulation of lnc-SPRYD7-1, also known as DLEU2. In
addition, CLLs with del13q showed the downregulation of lnc-
LIPG-3. This lncRNA has three different transcripts, including the
independent transcriptional unit SCARNA17 and the non-coding
RNA SNHG22, in the intron of which the SCARNA17 is located. Lnc-
LIPG-3 is also downregulated in CLL samples with del11q and 12+,
both of which showed an upregulation of lnc-AC004696.1-1. Only
two lncRNAs were differentially expressed in patients with del17p.
In particular, we found the downregulation of lnc-LTBP3-2 located
at 11q13 antisense to both NEAT1 and MALAT1, the latter being a
well-known putative oncogenic lncRNA found significantly corre-
lated with lnc-LTBP3-2 expression in our CLL data set (R= 0.54,
Po2.2e-16).
Finally, we investigated the expression of lncRNAs specifically
associated with the presence of NOTCH1 mutations
(Supplementary Table S9). Again, among the seven lncRNAs
differentially expressed, NOTCH1 mutated CLLs showed an
upregulation of lnc-IRF2-3, lnc-AC004696.1-1 and lnc-BACH1-1,
Figure 1. LncRNA expression profile of CLL and normal B-cells samples. (a) Hierarchical clustering of the 26 normal B-cell samples using the
141 lncRNAs most variable across the data set. The red line identified five branches related to the distinct normal B-cells subtypes. (b) Principal
component analysis (PCA) that includes CLL samples shows that CLLs are closer in a three-dimensional space of similarity to M, N and MZ
tonsillar B-lymphocytes than to other B-cell types, based on the expression of the 226 lncRNAs resulting as differentially expressed in the five
normal B-cell subset from the multiclass analysis. (c) A heatmap showing the differentially expressed lncRNAs in the training group of CLL
patients compared with normal (N) 'comparator' samples. For each lncRNA, information about chromosomal localization (Chr), alias name,
transcripts overlapping in sense or antisense (indicated as S or AS, respectively) direction is indicated.
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and a downregulation of lnc-C1orf132-1, all of which were found
to be deregulated in CLL subgroups with adverse prognostic
factors.
LncRNAs interplay with genes and miRNAs in CLL
To gain evidence of lncRNAs that might influence gene
expression, we evaluated the correlation between the expression
level of the 1852 lncRNAs and that of the 17 788 coding transcripts
unambiguously detected by the arrays. To be confident of
predicting lncRNA–gene relationship, we focused on an
lncRNAs/mRNAs ratio with a correlation coefficient 40.9
(Table 2), and found three distinct lncRNAs: (i) Lnc-AC004696.1-1
(see above) which positively correlated with its antisense over-
lapping gene ZNF667, suggesting a potential in cis regulation; (ii)
lnc-NDST3-1, downregulated in del13q and del11q CLLs (Table 1),
which positively correlated with the expression of RPL18A; and (iii)
lnc-cYorf15A.1-2 that highly correlated with the expression of four
genes located in sense or antisense orientation on chromosome Y
about 7 Mb apart, and with two other genes, RPS4Y1 and ZFY,
located on the short arm of chromosome Y. Since lnc-cYorf15A.1-2
and its correlated genes are expressed by males only, the
correlation coefficients were recalculated in male patients and
found to be below 0.8 for all of the six lncRNA–gene couples.
The relationship between lncRNAs and miRNAs also was studied
in all patients of the cohort.31 To test the transcriptional
relationships, the correlations between the expression levels of
any lncRNA and miRNA were computed first. We identified 861
lncRNA-miRNA couples significantly anti-correlated in our data-
base (q-valueo0.01). Then, one of the most common target
Table 1. LncRNAs resulting upregulated (↑) or downregulated (↓) from SAM analyses comparing CLLs with adverse and favorable prognostic factors
lncRNAa UM vs Mb del13 vs Negc del11 vs Negc 12+ vs Negc del17 vs Negc Chr Alias/overlapping transcriptd
CPNE1-2 ↑ ↑ ↑ 20q11 S to FER1L4 (P)
C20orf173-4 ↑ ↑ 20q11 FER1L4 (P) (RI)
AC004696.1-1 ↑ ↑ ↑ 19q13 ZNF667-AS1
ACTR1B-5 ↑ ↑ 2q11 S to ANKRD36B
IRF2-3 ↑ 4q35 Linc
BACH1-1 ↑ 21q21 LINC00189
FREM3-6 ↑ 4q31 AC097658.1 (P)
CD38-2 ↑ 4p15 TAPT1-AS1
TNFRSF13B-5 ↑ 17p11 TBC1D27 (UnP), TNFRSF13B (RI)
ZNF131-1 ↑ 5p12 LOC153684
C1orf132-1 ↓ 1q32 S to miR102 (miR-29B/29C)
KLHL9-1 ↓ 9p21 DKFZp686L0695
SNX29P2-3 ↑ ↑ 16p11 AC009093.1 (P)
GAS1-2 ↑e ↑ 9q21 Linc
VKORC1L1-3 ↑ 7q11 RP13-254B10.1 (PP)
SEL1L3-6 ↑ 4p15 (UnP)
SPRYD7-1 ↓ 13q14 DLEU2
LIPG-3 ↓ ↓ ↓ 18q21 SNHG22 (SCARNA17)
ATG12-3 ↓ ↓ 5q23 CTD-2287O16.1 (PP)
SYNCRIP-2 ↓ ↓ 6q12 SNHG5
NDST3-1 ↓ ↓ 4q26 SNHG8 (SNORA24)
LTBP3-2 ↓e ↓ 11q13 AS to NEAT1 and MALAT1
ATAD5-3 ↓e ↓ 17q11 SUZ12P1 (P)
ETNK2-4 ↓ 1q32 Linc
AC090699.1.1-1 ↓e ↓ 17q25 SNHG16
IQCG-11 ↑ 3q29 ANKRD18DP (P)
AC021860.1-2 ↑ 4p14 AS to KLF3
NANOGP1-1 ↑ 12p13 NANOGP1 (P)
SERPINB9-1 ↑ 6p25 S to miR-4645
JAM2-2 ↓ 21q21 MIR155HG
C9orf131-2 ↓ 9p13 RN7SL338P (M)
STYXL1-2 ↓ 7q11 TMEM120A (RI)
Abbreviations: PP, processed pseudogene; P, pseudogene; UnP, unprocessed pseudogene; M, miscellaneous RNA; RI, transcript with retained intron. alncRNAs
in bold resulted associated with PFS. bAnalysis performed in the del13 CLL subgroup. cFISH negative CLLs. dSense (S) to, or antisense (AS) to, overlapping
transcripts; Ensembl type. eResulted from SAM analysis but not with the top 10 score.
Table 2. LncRNAs highly correlated with transcripts
lncRNA Transcript lncRNA chr. lncRNA aliasa Transcript chr. Correlation coeff.b
AC004696.1-1 ZNF667 19q13 ZNF667-AS1 19q13 0.94
NDST3-1 RPL18A 4q26 SNHG8 19p13 0.91
Cyorf15A.1-2 DDX3Y Yq11 TXLNG2P Yq11 0.97
Cyorf15A.1-2 KDM5D Yq11 TXLNG2P Yq11 0.96
Cyorf15A.1-2 USP9Y Yq11 TXLNG2P Yq11 0.98
Cyorf15A.1-2 UTY Yq11 TXLNG2P Yq11 0.92
Cyorf15A.1-2 RPS4Y1 Yq11 TXLNG2P Yp11 0.96
Cyorf15A.1-2 ZFY Yq11 TXLNG2P Yp11 0.94
Chromosomal localization (Chr.) and alias name are indicated. aSense (S) to, or antisense (AS) to, overlapping transcripts. bP-value= 2.2e-16.
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prediction algorithms (RNA-22) was run on each significantly
correlated pair, using the miRNA sequences annotated on
miRbase v20 and the LNCipedia lncRNA sequences corresponding
to the fragments investigated by the probes on the array. Hence,
we identified 11 lncRNA-miRNA anti-correlated couples supported
by miRNA target prediction (q-valueo0.05; Table 3). Notably, we
found the couples miR-331-3p/lnc-LIPG-3 (lnc-LIPG-3 downregu-
lated in samples with del13q, del11q or 12+; Table 1), and
miR-574-3p/lnc-LINS-1 (miR-574-3p reported as upregulated in
UM-CLL patients).31
Identification of an lncRNA transcriptional profile with clinical
relevance
Since the cohort analyzed was recruited in a perspective study on
Binet A patients, we could investigate correlations between
lncRNA profiles and PFS. Clinical data were available for 209/217
CLL. To this aim, a globaltest was run on the 471 lncRNAs the
expression of which varied mostly over the data set. Eight lncRNAs
showed significant association with PFS (Po0.001;
Supplementary Table S10) and five had a significant predictive
value for PFS in univariate analysis (Table 4). The expression levels
of lnc-IRF2-3, lnc-AC004696.1-1, lnc-C1orf132-1 and KIAA1755-4
were validated by qRT-PCR, showing a good concordance
(Supplementary Figure S4 and Supplementary Table S11). Notably,
lnc-KIAA1755-4 corresponds to the SNORA71A that is processed
from the intronic region of the non-coding RNA SNHG17
(Supplementary Figure S4d).
Next, our analysis focused on lnc-IRF2-3 that had the highest
predictive value for PFS by univariate test and was highly
expressed in UM-CLLs. Interestingly, the highest lnc-IRF2-3
expression level was found in the subset of UM-CLL patients with
the shortest PFS (Figure 2a). However, its predictive power lost
strength (P= 0.051) after adjustment for covariate confounders,
particularly CD38, likely because high expression levels of CD38
and lnc-IRF2-3 define largely overlapping CLL subgroups
(Supplementary Figure S3). In order to improve the robustness
of the lncRNAs as PFS predictors, lnc-IRF2-3 was combined with a
second lncRNA from the group with the significant predictive
value (Table 4). We evaluated each of these lncRNAs in
combination with lnc-IRF2-3, based on the following scheme
defining groups as (i) high/high, (ii) low/low or (iii) discordant
expression levels. Among all the possible combinations tested, the
couple lnc-IRF2-3 and lnc-KIAA1755-4 determined the best
predictive model. Specifically, a better PFS corresponded to
patients with a concomitant low expression of both lncRNAs
(a 'low-risk' group, including 122 patients, 56%), whereas a worse
PFS was associated with their concomitant high expression ('high-
risk' group, 12 patients; Figure 2b). The 'intermediate-risk' group
(75 patients) was characterized by the discordant expression of
the two lncRNAs. The high-risk group had a hazard ratio of 8.05
(95% CI: 3.82–16.96; median PFS: 862 days), and the intermediate-
risk group of 2.27 (95% CI: 1.39–3.69; median PFS: 1678 days),
compared with the low-risk group (median PFS not reached).
Finally, multivariate regression analysis confirmed the indepen-
dence of the 2-lncRNA risk model from other known predictive
factors in CLL (IGHV mutational status, CD38 and ZAP70
expression, NOTCH mutation and unfavorable chromosomal
aberration as covariates; Table 5). Likewise, the 2-lncRNA risk
model resulted informative when compared with the recently
defined progression-risk score (PRS) based on the integration of
Table 4. LncRNAs with significant predictive value related to PFS in the univariate log-rank test
lncRNA Alias/overlapping transcript Chr. HR LO 95% CI UP 95% CI P-valuea
IRF2-3 Linc 4q35 3.67 2.14 6.28 2.14E-06
C1orf132-1 S to miR-102 1q32 0.36 0.22 0.59 5.49E-05
ADAP2-2 RN7SL138P 17q11 0.37 0.22 0.63 0.000245
AC004696.1-1 ZNF667-AS1 19q13 2.67 1.69 4.22 2.29E-05
KIAA1755-4 SNORA71A 20q11 2.21 1.39 3.50 0.000691
ZNF131-1 Uncharacterized loc. 5p11 2.07 1.31 3.25 0.0016
PTPDC1-7 AS to MIRLET7D 9q22 0.45 0.28 0.74 0.00184
MTMR2-1 Pseudogene 11q21 0.53 0.33 0.84 0.00691
aBased on the K-means clustering stratification of CLL cases into two groups according to lncRNAs expression level, five out of the eight lncRNAs had a
significant predictive value for PFS in the univariate log-rank test (Po0.001).
Table 3. LncRNAs highly correlated with miRNAs
lncRNA miRNA lncRNA Chr. lncRNA aliasa Correlation Target prediction
cor q-val lncRNA target sequence from/to q-val
C1ORF86-1:2 miR-221-3p 1p36 AS to PRKCZ − 0.27 0.007 (668, 690) 0.011
MAP1LC3B2-2:4 miR-30b-3p 12q24 Linc00173 − 0.27 0.007 (1890, 1911) 0.045
LIPG-3:2 miR-331-3p 18q21 SNHG22, SCARNA17 − 0.26 0.008 (2485, 2506) 0.013
MON2-2:2 miR-370-3p 12q14 S to miR-let7i − 0.27 0.007 (10737, 10759) 0.019
TFDP2-7:3 miR-486-3p 3q23 GK5 − 0.37 3.2E-05 (3303, 3321) 0.040
LINS-1:2 miR-574-3p 15q26 PRKXP1 − 0.28 0.004 (5285, 5306) o1E-06
DLK1-4:12 miR-628-3p 14q32 S to MEG3 − 0.26 0.010 (4377, 4397) 0.043
C22ORF32-1:6 miR-659-3p 22q13 Linc-OGFRP1 − 0.29 0.003 (2903, 2923) 0.023
SEC61G-12:1 miR-659-3p 7p12 RN7SKP218 − 0.27 0.008 (98, 120) 0.047
KIDINS220-6:14 miR-92a-1-5p 2p25 Linc00298 − 0.28 0.004 (184, 206) 0.011
SNHG15-1:8 miR-940 7p13 SNHG15 − 0.35 1.0E-04 (2090, 2113) 0.049
Chromosomal localization (Chr.) and alias name are indicated. aSense (S) to, or antisense (AS) to, overlapping transcripts.
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clinical, laboratory and biological parameters independently
associated with PFS38 (Table 5).
To gain insight into their possible role in CLL pathophysiology,
we evaluated in silico whether the modulation of lnc-IRF2-3 or lnc-
KIAA1755-4 might correspond to transcriptional signatures
possibly associated with functional categories. Specifically, we
ranked genes according to decreasing Pearson’s correlation with
the expression level of lnc-IRF2-3 or lnc-KIAA1755-4 in the 217
samples using the gene set enrichment analysis software to
identify a priori-defined sets of genes showing concordant
modulation. We found lnc-IRF2-3 associated with 18 gene sets
(1 from Kegg and 17 from Hallmarks data sets; Supplementary
Table S12; representative examples in Figure 3a), virtually all
related to the metabolism of amino acids, sugars and lipids.
Interestingly, lnc-IRF2-3 resulted associated with the gene set
linked to primary immunodeficiency, and with genes encoding
proteins over-represented on the apical surface of epithelial cells
(Figure 3a). Concerning lnc-KIAA1755-4, we identified 30 gene sets
(6 from Kegg and 24 from Reactome data sets; Figure 3b and
Supplementary Table S13), 10 of which including genes mainly
encoding for ribosomal proteins, and thus principally associated
with ribosome formation and translational processes. Notably, 12
gene sets highly enriched in genes encoding for histone
components are associated with transcriptional processes, chro-
mosomes and telomeres maintenance, and telomeres packaging.
DISCUSSION
This study provided a comprehensive analysis of the transcrip-
tional profile of lncRNAs in a large cohort of early-stage CLL
patients.
First, we unraveled a 24-lncRNA signature specifically deregu-
lated in CLL compared with a normal B-cell counterpart. The
identification of the normal counterpart is currently a debated
issue.37,39 Although based on a limited number of normal samples,
our analysis revealed that the lncRNA expression profile of
leukemic cells is more similar to N, MZ and M B-cells than to GC
cells, total pBCs or PCs, as previously observed in our previous
studies for miRNA and snoRNA expression patterns.25,31 Therefore,
lncRNAs that significantly discriminate CLL cells and N, MZ and M
B-cells, may be of relevance in disease pathogenesis. Importantly,
the 24-lncRNA model was validated on an independent data set.
Among the 24 lncRNAs, we highlighted the downregulation of lnc-
TOMM7-1, mapped to chromosome 7p antisense to the
interleukin-6 (IL6) gene, which promotes B-cell lineage prolifera-
tion and differentiation. Lnc-TOMM7-1 may participate in IL6
transcriptional regulation and therefore may have a pathogenic
role, given the potential function of IL6 as an autocrine growth
factor in CLL.40 The lncRNAs classifier also included lnc-SNX29P2-3
Figure 2. A 2-lncRNA risk model in CLL. (a) Progression-free survival of IGHV unmutated (UM)-CLL grouped according to lnc-IRF2-3 expression levels.
Kaplan–Meier estimated curves of the two groups defined by lnc-IRF2-3 high (gray) and low (black) expression levels. (b) Kaplan–Meier estimated
curves of the 2-lncRNA model. CLL are divided into a low-risk group (low expression of both lncRNAs), an intermediate group (high expression of one
of the two lncRNAs) and a high-risk group (high expression of both lncRNAs). The high-risk group has a median PFS of 862 days.
Table 5. Multivariate analysis comparing the 2-lncRNA risk model with
prognostic variables or with PRS in CLL series
Variable HR LO 95% CI UP 95% CI P-value
I-RISK GROUPa 2.32 1.30 4.12 0.0043
H-RISK GROUPa 7.64 2.66 21.92 2E-04
UM-CLL 1.38 0.65 2.92 0.396
ZAP70+ 0.84 0.43 1.60 0.596
del17+ 1.67 0.54 5.11 0.366
del11+ 3.98 1.72 9.19 0.001
12+ 1.28 0.57 2.84 0.541
CD38+ 1.00 0.99 1.01 0.243
NOTCH-MUT+ 0.94 0.49 1.81 0.861
I-RISK GROUPa 1.54 0.85 2.78 0.149
H-RISK GROUPa 3.88 1.63 9.18 2E-03
PRS 3.18 2.08 4.83 6.5E-08
aIntermediate-risk or high-risk group in the 2 lncRNA-risk model.
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and lnc-SEL1L3-6 which were upregulated in CLL samples. This
finding, contradictory to that found by us in PC dyscrasia where
the two lncRNAs are downregulated in pathological samples,36
suggests that the role of lncRNA likely depends on the cellular
context.
Despite the homogeneity of the lncRNA expression profile,
possibly enhanced by testing samples of patients uniformly at
their early disease stages, specific lncRNA signatures were
detected in subgroups of CLL stratified according to cellular,
molecular and cytogenetic markers. As expected, some lncRNAs
were recurrently associated with the presence of adverse
prognostic markers. Among them, it is worth mentioning lnc-
AC004696.1-1, also known as ZNF667-AS1, the highest expression
of which was found in UM-CLLs as also showed by previous
studies,41 and was also negatively associated with a short PFS.
Interestingly, two recent studies have reported epigenetic
silencing of this lncRNA during the immortalization of human
mammary epithelial cells as well as in a panel of cancer types
including acute myeloid leukemia, diffuse large B-cell lymphoma42
and solid tumors.43 These findings seem contradictory to the
situation that we and others41 have found in CLL with adverse
prognosis for which high lnc-AC004696.1-1 expression was
compatible with a transformed and potentially aggressive
condition, again supporting the notion that the role played by
lncRNA likely depends on the cellular context. Notably, in our CLL
database, lnc-AC004696.1-1 expression highly correlated with that
Figure 3. Representative enrichment plots of gene sets significantly up- and downregulated in CLL with increasing expression levels of lnc-
IRF2-3 (a) or lnc-KIAA1755-4 (b) detected by gene set enrichment analysis. The green curves show the enrichment score and reflect the degree
to which each gene (black vertical lines) is represented at the bottom of the ranked gene list.
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of the ZNF667 gene (Table 2), with which it shares (head to head) a
CpG island. A co-regulatory mechanism of the two transcripts
needs to be investigated, but it is of interest the evidence that
ZNF667 inhibits the expression of the anti-apoptotic gene BAX in
rats.44
Albeit it is feasible that lncRNAs are engaged in miRNA
mediated interactions,19 their contribution is yet poorly explored
in general, and in CLL in particular. To provide insights into this
aspect, we studied the expression correlation of lncRNAs and
miRNAs in paired samples, with the support of target prediction
analysis. Among the 11 pairs reported in Table 3, particularly
relevant appear miR-574-3p/lnc-LINS-1 and miR-331-3p/lnc-LIPG-
-3. MiR-574-3p is upregulated in UM-CLL and is associated with a
major risk of disease progression in the same cohort of CLL.31
Considering that miR-574-3p has been described as a tumor
suppressor miRNA in different types of solid tumors,45 we can
hypothesize that in CLL, lnc-LINS-1 may play a fine-tuning role in
the regulatory circuitry including miR-574-3p and its target genes.
Considering the other miRNA/lncRNA pair, lnc-LIPG-3 expression
was downregulated in samples with del13q, del11q or 12+
(Table 1). While existing data describe miR-331-3p as one of the
most expressed miRNA in CLL as compared with normal
peripheral CD19+ B-cells,46 our results do not highlight such a
great difference with the normal comparators (Supplementary
Figure S5) and is in all likelihood due to the different B-cell
subpopulation chosen as normal controls. Notably, a network
between miR-331-3p and lncRNAs has been already described in
gastric cancer, where miR-331-3p has been proven to target the
HOTAIR lncRNA that, in turn, functions as a competing endogen-
ous RNA (ceRNA) to regulate HER2 expression by sponging
miR-331-3p.47
Finally, we have proposed a 2-lncRNA risk model, based on the
expression of lnc-IRF2-3 and lnc-KIAA1755-4, able to stratify our
series of early-stage Binet A CLL patients into three different
prognostic groups. The model identifies a very high-risk group
characterized by the concomitant high expression of both
lncRNAs. Notably, the model is independent of the common
prognostic markers and of a recently defined progression-risk
score.38 Information on lnc-IRF2-3 is still very limited. Ferreira
et al.41 reported its high expression in prognostically poor UM-
patients (Supplementary Table S2). Conversely, lnc-IRF2-3 is
progressively downregulated trough the more aggressive stages
of PC dyscrasia.36 Such a discrepancy maybe due to the cellular
context as previously hypothesized for lnc-SNX29P2-3 and lnc-
SEL1L3-6. Our gene set enrichment analysis results pointed out
that in CLL lnc-IRF2-3 expression is associated with 18 gene sets
the majority of which (15) are related to the metabolism of amino
acids, sugars and lipids. Among the remaining ones, it is of note
the gene set linked to primary immunodeficiency given that it
includes genes related to CLL biology such as Zap70, CD19, BTK
and CD79A genes. In addition, we found a specific association
between lnc-IRF2-3 expression and the gene set that included
genes related the apical surface of epithelial cells, such as those
important for determining cell polarity. Overall these data prompt
to further investigation of the functional role of lnc-IRF2-3 in the
biology and the progression of the disease. Lnc-KIAA1755-4 is
processed from the intronic region of the non-coding RNA
SNHG17 and actually corresponds to SNORA71A, thus belonging
to a class of molecules essentially localized in the nucleolus where
they function as guide RNAs for the post-transcriptional modifica-
tion of ribosomal RNAs. In particular, SNORA71A is predicted to
guide the pseudouridylation of U406 in 18S rRNA.48 The potential
clinical relevance of this type of ncRNA family in cancer and CLL
have been previously reported by us and others.25,49 Functional
analysis of genes whose expression might be related to lnc-
KIAA1755-4 highlighted enrichments in genes encoding for
histone components, genes associated with transcriptional
processes, chromosome and telomere maintenance, and
telomeres packaging, all of which are biological processes
frequently affected during cellular immortalization and tumor
progression.
Overall, our findings offer a portrait of the lncRNA transcrip-
tional landscape in CLL, ultimately providing insights into the
biological mechanisms involving the non-coding fraction of the
transcriptome and contributing to suggest novel putative
molecular markers associated with high-risk course of the disease.
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